ABUS vs DAAQU โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while DAAQU counters with relative strength in Momentum & Technical. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus DAAQU at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABUS sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against DAAQU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABUS | DAAQU | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $627.7M | N/A | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | 3.7x | N/M | Lower Multiple | ABUS |
| Forward P/E Ratio Valuation | 10.2x | N/M | Lower Multiple | ABUS |
| Revenue Growth (YoY) Growth | -43.5% | N/A | Higher Growth | ABUS |
| Operating Margin (TTM) Profitability | 80.1% | N/A | Higher Margin | ABUS |
| Net Profit Margin Profitability | 121.2% | N/A | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | 269.6% | N/A | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 29% ($4โ$5) | 70% ($7โ$12) | Stronger Trend | DAAQU |
| Beta / 30D Volatility Risk Regime | 1.10ฮฒ ยท 48% Vol | -0.36ฮฒ ยท 150% Vol | Lower Realized Risk | ABUS |
| Unified Institutional Score Composite Signal | 50.6 / 100 (HOLD) | 45.6 / 100 (HOLD) | Higher Composite | ABUS |